Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.57 |
| ▸ | ALPL | P05186 | 3/20 | 0.50 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.47 |
| ▸ | CCR4 | P51679 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3826040 | 0.91 | ALPL (0.54) | PPARGCYP3A4ALPLSLC40A1 | |
| SCHEMBL3825143 | 0.91 | PPARG (0.47) | PPARGCYP3A4ALPL | |
| SCHEMBL3827203 | 0.87 | KMT2A (0.51) | PPARGALPL | |
| SCHEMBL3826359 | 0.87 | PPARG (0.61) | PPARGCYP3A4ALPL | |
| SCHEMBL3827574 | 0.86 | PPARG (0.49) | PPARGCYP3A4ALPL | |
| SCHEMBL3827235 | 0.85 | SLC22A12 (0.46) | PPARGCYP3A4ALPLCCR4 | |
| SCHEMBL3822177 | 0.85 | PGR (0.49) | PPARGCYP3A4ALPLCCR4 | |
| SCHEMBL14689434 | 0.85 | LMNA (0.53) | PPARGALPL | |
| SCHEMBL3825873 | 0.84 | ALPL (0.64) | ALPL | |
| SCHEMBL14689561 | 0.84 | SLC22A12 (0.55) | PPARGALPLSLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013117963-A1 | STABLE ORAL TABLET DOSAGE FORM OF AN ANTIDIABETIC COMPOUND | Piramal Enterprises Limited (IN) | 2013-08-15 | — | — | WO | claimed |
| US-20130040988-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Enterprises Limited (IN) | 2013-02-14 | — | — | US | claimed |
| US-8269010-B2 | 3-amino-pyridine derivatives for the treatment of metabolic disorders | PIRAMAL HEALTHCARE LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| EP-2256496-A2 | Method for identifying compounds that act as insulin-sensitizers | Piramal Life Sciences Limited (IN) | 2010-12-01 | — | — | EP | claimed |
| US-20090318465-A1 | METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS | Piramal Enterprises Limited (IN) | 2009-12-24 | — | — | US | claimed |
| US-20090247574-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Enterprises Limited (IN) | 2009-10-01 | — | — | US | claimed |
| EP-2094687-A1 | 3 -AMINO- PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Life Sciences Limited (IN) | 2009-09-02 | — | — | EP | claimed |
| EP-2064545-A2 | METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS | Piramal Life Sciences Limited (IN) | 2009-06-03 | — | — | EP | claimed |
| WO-2008035309-A2 | METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-03-27 | — | — | WO | claimed |
| WO-2008035306-A1 | 3 -AMINO- PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-03-27 | — | — | WO | claimed |
| WO-2013117963-A1 | STABLE ORAL TABLET DOSAGE FORM OF AN ANTIDIABETIC COMPOUND | Piramal Enterprises Limited (IN) | 2013-08-15 | — | — | WO | disclosed |
| US-20130040988-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Enterprises Limited (IN) | 2013-02-14 | — | — | US | disclosed |
| US-20120309786-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Enterprises Limited (IN) | 2012-12-06 | — | — | US | disclosed |
| US-8269010-B2 | 3-amino-pyridine derivatives for the treatment of metabolic disorders | PIRAMAL HEALTHCARE LIMITED (IN) | 2012-09-18 | — | — | US | disclosed |
| EP-2064545-B1 | METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS | PIRAMAL LIFE SCIENCES LTD (IN) | 2012-07-04 | — | — | EP | disclosed |
| US-20090247574-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Enterprises Limited (IN) | 2009-10-01 | — | — | US | disclosed |
| EP-2094687-A1 | 3 -AMINO- PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Life Sciences Limited (IN) | 2009-09-02 | — | — | EP | disclosed |
| EP-2064545-A2 | METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS | Piramal Life Sciences Limited (IN) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008035309-A2 | METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008035306-A1 | 3 -AMINO- PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040988-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, ABAT, GOT2 | PPARG 69/4885CYP3A4 118/4885ALPL 893/4885 |
| US-20120309786-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, ABAT, PYGL | PPARG 62/4885CYP3A4 134/4885ALPL 751/4885 |
| US-20090318465-A1 | METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS | GPR119, SLC2A4, INSR | PPARG 377/4885CYP3A4 672/4885ALPL 450/4885 |
| US-20090247574-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, ABAT, PDXK | PPARG 91/4885CYP3A4 207/4885ALPL 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.